Quel est le prix pour AbbVie Inc. (ABBV)

Le prix pour AbbVie Inc. (ABBV) est $263.25

Quelle est la capitalisation boursière pour AbbVie Inc. (ABBV)

La capitalisation boursière pour AbbVie Inc. (ABBV) est $465.10B

AbbVie Inc. (ABBV) Rendement du Dividende

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Année	Rendement du dividende	Changez
2026 (TTM)	2.61%	-9.06%
2025	2.87%	-18.23%
2024	3.51%	-8.83%
2023	3.85%	9.69%
2022	3.51%	-9.07%
2021	3.86%	-10.65%
2020	4.32%	-10.93%
2019	4.85%	23.41%
2018	3.93%	47.74%
2017	2.66%	-27.32%
2016	3.66%	7.02%
2015	3.42%	34.12%
2014	2.55%	-16.12%
2013	3.04%	0.00%
2012	0.00%	0.00%
2011	0.00%	0.00%
2010	0.00%	0.00%
2009	0.00%	0.00%

Année

Rendement du dividende

Changez

2026 (TTM)

2.61%

-9.06%

2025

2.87%

-18.23%

2024

3.51%

-8.83%

2023

3.85%

9.69%

2022

3.51%

-9.07%

2021

3.86%

-10.65%

2020

4.32%

-10.93%

2019

4.85%

23.41%

2018

3.93%

47.74%

2017

2.66%

-27.32%

2016

3.66%

7.02%

2015

3.42%

34.12%

2014

2.55%

-16.12%

2013

3.04%

0.00%

2012

0.00%

0.00%

2011

0.00%

0.00%

2010

0.00%

0.00%

2009

0.00%

0.00%

Entreprise	Rendement du dividende	Pays
Eli Lilly and Company LLY.US	0.59%	US
Johnson & Johnson JNJ.US	1.98%	US
Roche Holding AG RO.SW	2.69%	CH
Merck & Co., Inc. MRK.US	2.35%	US
Novartis AG NOVN.SW	2.80%	CH

Entreprise

Rendement du dividende

Pays

Eli Lilly and Company

LLY.US

0.59%

Johnson & Johnson

JNJ.US

1.98%

Roche Holding AG

RO.SW

2.69%

Merck & Co., Inc.

MRK.US

2.35%

Novartis AG

NOVN.SW

2.80%

AbbVie Inc.

ABBV

Catégorie